Fig. 5.

Comparison of the associations of prior CVD/CKD/no prior CVD/CKD and treatment with degludec/glargine U100 with the risks of MACE, cardiovascular death, all-cause mortality and the rate of severe hypoglycemia. *P value for interaction between treatment and baseline CVD and CKD status;^†rate of events/100 patient years of exposure. Times from randomization to first MACE, cardiovascular death, and all-cause mortality were analyzed using Cox proportional hazard regression models with treatment, baseline GFR category, and interaction between treatment and baseline GFR category as fixed factors. The number of severe hypoglycemic events was analyzed using a negative binomial regression model with log-link function and the logarithm of the duration of observation time (100 patient years) as offset in addition to randomized treatment, baseline GFR category, and their interactions. Data on the proportion of patients with events and the rate of severe hypoglycemic events are based on observed numbers. CI confidence interval, CVD cardiovascular disease,CKD chronic kidney disease, glargine U100 insulin glargine 100 units/mL, MACE major adverse cardiovascular events